Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

201970 citationsJournal Articlegold Open Access

Authors

Mark N. Stein · Rutgers, The State University of New Jersey

Jyoti Malhotra · Rutgers, The State University of New Jersey

Rohinton S. Tarapore · Oncoceutics (United States)

Usha Malhotra · Rutgers, The State University of New Jersey

Ann W. Silk · Rutgers, The State University of New Jersey

Nancy Chan · Rutgers, The State University of New Jersey

Lorna Rodriguez

Abstract

NCT02250781 (Oral ONC201 in Treating Patients With Advanced Solid Tumors), NCT02324621 (Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors).

Topics & Keywords

PARP inhibition in cancer therapy Immunotherapy and Immune Responses Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 7, Issue 1, pp. 136-136

DOI: 10.1186/s40425-019-0599-8

Field-Weighted Citation Impact: 4.04